BRAFTOVI

Encorafenib 50mg, Oral capsule

Cannabis

· Severity: Major

· Notes for Consumers: Discuss cannabis use with your care team. The effects of cannabis may be altered if used with your medication.

· Notes for Professionals: Advise patients to avoid cannabis use during encorafenib treatment. Concomitant use may decrease the concentration of some cannabinoids and alter their effects. The cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are CYP3A substrates and encorafenib is a strong CYP3A inducer. Concomitant use of a cannabinoid product containing THC and CBD at an approximate 1:1 ratio with another strong CYP3A inducer decreased THC, 11-OH-THC, and CBD peak exposure by 36%, 87%, and 52% respectively.

Encorafenib 50mg, Oral capsule

Grapefruit juice

· Severity: Major

· Notes for Consumers: Do not drink grapefruit juice or eat grapefruit while taking this medication. Grapefruit may alter the effects of your medication. Serious side effects may occur. Contact your care team right away if you experience new or worsening side effects.

· Notes for Professionals: Advise patients to avoid grapefruit and grapefruit juice during encorafenib treatment due to the risk of increased encorafenib exposure and adverse reactions. Encorafenib is a CYP3A substrate and grapefruit juice is a CYP3A inhibitor.

<b>DISCLAIMER:</b><em> This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.</em>